In vivo, it inhibits PKCι/ζ, downregulates the phosphorylation of CDK7 and CDK2, blocks the cell cycle at the G0/G1 phase, and induces PARP cleavage (an apoptotic marker), thereby reducing tumor cell proliferation. The gene discussed is PRKCA; the disease is neoplasm.